Starpharma's SPL7013 COVID-19 Nasal Spray Virucidal Against SARS-CoV-2

Author's Avatar
Sep 14, 2020
Article's Main Image

Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has completed additional antiviral testing for SPL7013 against SARS‑CoV-2 in studies conducted in the laboratory of internationally recognised virology researcher, Professor Philippe Gallay, at the renowned Scripps Research Institute in the US.